Home › Glioma › Connecticut
Glioma clinical trials in Connecticut
6 studies for Glioma are looking for participants at sites in Connecticut.
Cities in Connecticut
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Yale Cancer Center, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07326566Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
- Yale University, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07703436SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Yale University, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519Language Network Prehab Via fMRI Neurofeedback
- Yale School of Medicine, New Haven
Recruiting
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07488780A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Norwalk Hospital, Norwalk
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
- Hartford Healthcare Alliance (Data Collection Only), Hartford
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05188508From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.